Compare Caesars Entertainment Inc (CZR) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Caesars Entertainment Inc trades at $29.49 (market cap $6.02B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 9.8× Caesars Entertainment Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Caesars Entertainment Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| CZR | TAK | |
|---|---|---|
Market Cap | $6.02B | $58.74B |
Volume | 6,412,151 | 3,110,994 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $19.05 |
52-Week Low | $18.14 | $13.23 |
Typical Hold Time | 31 Days | 1 Days |
Enterprise Value | $29.91B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CZR trades at $29.50, up slightly by 0.03% today, with a bearish technical signal and neutral oscillators. The company reported a net loss of $502 million in 2025, missing earnings estimates for three consecutive quarters, while revenue remains stable near $11.5 billion. A pending merger with Fertitta Entertainment at $31.00 per share is under regulatory review, with several law firms investigating the deal's fairness.
CZR faces headwinds from persistent losses and high debt, but the merger offer provides a near-term price floor. Upside depends on operational turnaround and deal approval, while risks include earnings volatility and regulatory hurdles. Analyst consensus is mixed, with a hold-heavy rating and a $30.75 price target slightly above current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
